

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

H. William BOSCH et al.

Title:

NOVEL GLIPIZIDE COMPOSITIONS

Appl. No.:

10/701,064

Filing Date:

11/05/2003

Examiner:

Susan T. TRAN

Art Unit:

1615

Confirmation No.

6295

#### **TERMINAL DISCLAIMER**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Your Petitioner, Elan Pharma International Limited, having its principal place of business at Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland, represents that it is the owner of the entire right, title, and interest in and to U.S. Patent Application Serial No. 10/701,064, filed 11/05/2003, (which is a continuation of U.S. Patent Application No. 09/337, 675; filed 07/16/2003;) by virtue of an Assignment filed and recorded on 05/03/2004, on Reel/Frame 015294/0735, in the United States Patent and Trademark Office, a copy of which is attached hereto as APPENDIX A. Further, your Petitioner represents that it is the owner of U.S. Patent Application No. 10/619,539, filed 07/16/2003, by virtue of an Assignment filed and recorded on 08/18/2004, on Reel/Frame 015072/0837, in the United States Patent and Trademark Office, as recorded in the Patent Assignment Abstract of Title on the USPTO web site, a copy of which is attached hereto as APPENDIX B.

Your Petitioner, Elan Pharma International Limited, hereby disclaims the terminal part of the term of any patent granted on U.S. Patent Application 10/701,064 which would extend beyond the full statutory term, as shortened by any terminal disclaimer, of any

patent granted on U.S. Patent Application 10/619,539, and hereby agrees that any patent so granted on U.S. Patent Application 10/701,064 shall be enforceable only for and during such period that the legal title to any patent granted on U.S. Patent Application 10/619,539 shall be the same as the legal title to any patent granted on U.S. Patent Application 10/701,064, this agreement to run with any patent granted on U.S. Patent Application 10/701,064 and to be binding upon the grantee, its successors or assigns.

In making the above disclaimer, Petitioner does not disclaim any terminal part of any patent granted on U.S. Patent Application 10/701,064, prior to the full statutory term of any patent granted on U.S. Patent Application 10/619,539 as defined in 35 U.S.C. §§ 154-156 and 173, in the event that any patent granted on U.S. Patent Application 10/619,539 expires for failure to pay a maintenance fee, is held unenforceable or is found invalid in a final judgment by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321(a), has all claims canceled by a reexamination certificate or as a result of an interference proceeding, or is otherwise not deemed to provide the rights conveyed by 35 USC § 154, prior to the full statutory term of any patent granted on U.S. Patent Application 10/619,539 as defined in 35 USC §§ 154-156 and 173, except for the separation of legal title stated above. Further, Petitioner does not disclaim any terminal part of a patent granted on U.S. Patent Application 10/701,064 that would extend beyond the present termination of any patent granted on U.S. Patent Application 10/619,539, in the event that such present term is extended by virtue of compliance with the conditions for term extension of any present or future patent term extension provisions of the patent law, including but not limited to 35 U.S.C. §§ 155, 155A or 156, and without waiving Petitioner's right to extend the term of a patent granted on U.S. Patent Application 10/701,064 to the extent provided by law.

The undersigned, being the Attorney of Record for U.S. Patent Application 10/701,064, and duly authorized to act on behalf of Petitioner, certifies that she has reviewed the Assignments attached as APPENDICES A and B, and to the best of her knowledge and belief, legal title to U.S. Patent Application 10/701,064 and any patent granted on U.S. Patent Application 10/619,539 rests with Petitioners, Elan Pharma International Limited. The

undersigned declares that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the above-identified application or any patent issuing therefrom.

Respectfully submitted,

MidMMul

Date

FOLEY & LARDNER LLP

Customer Number: 31049

Telephone:

(202) 672-5538

Facsimile:

(202) 672-5399

Ву

Michele M. Simkin Attorney for Applicants

Registration No. 34,717

# APPENDIX A



#### UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

OCTOBER 27, 2004

PTAS



FOLEY & LARDNER MICHELE M. SIMKIN WASHINGTON HABROUR 3000 K STREET, N.W., SUITE 500 WASHINGTON, D.C. 20007-5143

> UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 05/03/2004

REEL/FRAME: 015294/0735

NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

BOSCH, H. WILLIAM

DOC DATE: 11/12/2003

ASSIGNOR:

RYDE, NIELS P.

DOC DATE: 11/14/2003

ASSIGNEE:

ELAN PHARMA INTERNATIONAL LIMITED WIL HOUSE, SHANNON BUSINESS PARK SHANNON, CO. CLARE, IRELAND

SERIAL NUMBER: 10701064

FILING DATE: 11/05/2003

PATENT NUMBER:

ISSUE DATE:

TITLE: NOVEL GLIPIZIDE COMPOSITIONS

015294/0735 PAGE 2

MAURICE CARTER, PARALEGAL ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS

·	05-06-	2004		Atty. Dkt. No. 029318-097
FORM PTO-1595 (modified) (Rev 6-93)				U.S. DEPARTMENT OF COMMERC
(Rev 6-93) REC			HEET	Patent and Trademark Off
	- 102/3	3864		
To the Director of the United States Paten	t aiark Office:	Please record the a	attached origi	nal documents or copies thereof.
1. Name of conveying party(isc).  H. William Bosch	N ES	2. Name and ad	dress of rec	eiving party(ies):
Niels P. Ryde ( 14 <sup>3)</sup> 0 0				
TATRICE TRACE	W. W. S.		, Shannoi	tional Limited n Business Park
5.3.04		Ireland	oo. Ciale	
	NO			
3. Nature of conveyance:  ASSIGNMENT  Execution Date:				
November 12 and 14, 2	2003	Additional name(s	s) & address	s(es) attached? NO
. Application number(s) or patent number	er(s):		· · · · · · · · · · · · · · · · · · ·	
If this is being filed together with a new	application, the execu	ution date of the a	pplication is	:
A. Patent Application Number(s):		B. Patent Number(s):		
10/701,064				
	Additional numbers	ottocheda NO		
5. Name and address of party to whom correspondence			£ ===!:==+:=	
concerning document should be mailed				ns/patents involved: 1
Michele M. Simkin	1	7. Total fee (37 C	.F.R. § 3.41	): \$40.00
FOLEY & LARDNER LLP Washington Harbour	\ 2	X Check Enclo	sed	
3000 K Street, N.W., Suite 50	o	Charge to de	eposit accou	int
Washington, D.C. 20007-514	3 8	<ol><li>Deposit account</li></ol>	nt number:	19-0741
	DO NOT USE T	HIS SPACE		
Statement and signature:  To the best of my knowledge and a ppy of the original document. The Comm a required in this matter to the above-iden	ISSION <del>a</del> r is namny airti	indiand to chame	and correct a	and any attached copy is a true aal recordation fees which may
Michele M. Simkin	- Midu	4 MM	ulia	5/3/04
Name of person signing		Signature		Date
_	otal number of pages	including cover st		
		THE POST OF THE PROPERTY.	ieet, amachi	ments and document: 2

002.1190871.1

01 FC:8021

40.00 DP

Atty. Docket No.: 029318-0978

### ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor has sold and assigned, and by these presents hereby sells and assigns, unto

ELAN PHARMA INTERNAT WIL House, Shannon Business	IONAL, LTD. Park, Shannon, Co. Clare, Ireland
ors and assigns, the entire right, title and ritories and Possessions thereof and all f	interest, so far as concerns the United States oreign countries in and to the invention in
NOVEL GLIPIZIDE COMPOSITION	IS
in this United States Patent Application	
□ executed concurrently herewith □ executed on □ Serial No. 10/701,064	Filed 11/05/2003
	will House, Shannon Business ons and assigns, the entire right, title and ritories and Possessions thereof and all f NOVEL GLIPIZIDE COMPOSITION in this United States Patent Application

said application for United States Letters Patent, including all divisional, renewal, substitute, continuation and Convention applications based in whole or in part upon said inventions or upon said applications, and any and all Letters Patent and reissues and extensions of Letters Patent granted for said inventions or upon said applications and every priority right that is or may be predicated upon or arise from said inventions, said applications, and said Letters Patent; said Assignee being hereby authorized to file patent applications in any or all countries on any or all said inventions in the name of the undersigned or in the name of said Assignee or otherwise as said Assignee may deem advisable, under the International Convention or otherwise; the Commissioner of Patents and Trademarks of the United States of America being hereby authorized to issue or transfer all said Letters Patent to said Assignee in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the undersigned, but also that such assigned right is not encumbered by any grant, license, or other right theretofore given, and that the undersigned will do all acts reasonably serving to ensure that the said inventions, patent applications and Letters Patent shall be held and enjoyed by said Assignee as fully and entirely as the same could have been held and enjoyed by the undersigned if this assignment had not been made, and particularly to execute and deliver to said Assignee all lawful documents including petitions, specifications, oaths, assignments, invention disclaimers, and lawful affidavits in form and substance which may be requested by said Assignee, to furnish said Assignee with all facts relating to said inventions or

the history thereof and any and all documents, photographs, models, samples or other physical exhibits which may be of said inventions, and to testify in any proceedings relating to said inventions, patent applications and Letters Patent.

The undersigned hereby grant the firm of FOLEY & LARDNER the power to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

NAMES AND STORY OF THE PROPERTY OF THE PROPERT				
NAMES AND SIGNATURES OF INVENTORS				
Name: H. William Bosch	Signature: A. William Booch	Date: Nov. 12.2003		
Name: Niels P. Ryde	Signature: Nuls P. Roll	Date: Nov. 14, 2003		
Name:	Signature:	Date:		
NAMES AND SIGNATURES OF WITNESSES				
Name: CAROL WRAY	Signature:	Date: NOV 12, 2003		
Name: CAROL WFAY	Signature: LOG	Date: Nov 14, 2003		

Note: Prima facie evidence of execution may optionally be obtained by execution of this document before a U.S. Consul or before a local officer authorized to administer oaths whose authority is proved by a certificate from a U.S. Consul.

IPT-407:4/90(1)(modified)

## **APPENDIX B**



#### **United States Patent and Trademark Office**

Home | Site Index | Search | Guides | Contacts | eBusiness | eBiz alerts | News | Help



#### Assignments on the Web > Patent Query

## Patent Assignment Abstract of Title

NOTE: Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

**Total Assignments: 1** 

Application #: 10619539 Filing Dt: 07/16/2003 Patent #: NONE **Issue Dt:** 

Publication #: US20040258757 Pub Dt: 12/23/2004

Inventors: H. William Bosch, Matthew R. Hilborn, Douglas C. Hovey, Laura J. Kline, Robert W. Lee et al

Title: Liquid dosage compositions of stable nanoparticulate active agents

Assignment: 1

Reel/Frame: 015072/0837 Recorded: 08/18/2004 Pages: 9

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: BOSCH, H. WILLIAM Exec Dt: 07/23/2003

HILBORN, MATTHEW R. **Exec Dt:** 07/23/2003

HOVEY, DOUGLAS C. Exec Dt: 07/23/2003

KLINE, LAURA J. Exec Dt: 07/23/2003

LEE, ROBERT W. Exec Dt: 07/29/2003

PRUITT, JOHN D. Exec Dt: 07/23/2003 Exec Dt: 07/23/2003 RYDE, NIELS P.

RYDE, TUULA A. Exec Dt: 07/23/2003

Exec Dt: 08/13/2003 XU, SHUQIAN

Assignee: ELAN PHARMA INTERNATIONAL, LTD.

WIL HOUSE

SHANNON BUSINESS PARK

SHANNON, CO. CLARE, IRELAND

Correspondent: FOLEY & LARDNER LLP

MICHELE M. SIMKIN WASHINGTON HARBOUR

3000 K STREET, N.W., SUITE 500 WASHINGTON, D.C. 20007-5143

Search Results as of: 03/23/2007 02:27 PI

If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. Web interface last modified: February 22, 2007 v.2.0

| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT